Fenofibrate News and Research

RSS
Fenofibrate is a drug used to treat high levels of cholesterol and triglycerides in the blood. Fenofibrate is being studied in the treatment of advanced cancers in young patients and in the treatment of other conditions. It is a type of antilipidemic agent. Also called Lofibra and TriCor.
LMRI scientists discover cause of debilitating eye disease

LMRI scientists discover cause of debilitating eye disease

First genetic cause for a rare eye disease discovered

First genetic cause for a rare eye disease discovered

TSRI chemists invent new method that simplifies late-stage modification of drug molecules

TSRI chemists invent new method that simplifies late-stage modification of drug molecules

Fenofibrate drug may reduce risk of cardiovascular events in patients with type 2 diabetes

Fenofibrate drug may reduce risk of cardiovascular events in patients with type 2 diabetes

ACCORDION study shows lowering blood glucose can reduce progression of diabetic retinopathy

ACCORDION study shows lowering blood glucose can reduce progression of diabetic retinopathy

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Promising new therapeutic strategy for chronic kidney disease

Promising new therapeutic strategy for chronic kidney disease

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Epicure project: an interview with Frédéric Cren

Epicure project: an interview with Frédéric Cren

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Impax Laboratories records adjusted net loss of $1.6 million in fourth quarter 2013

Impax Laboratories records adjusted net loss of $1.6 million in fourth quarter 2013

FDA issues final approval for Lupin's sNDA for Antara capsules

FDA issues final approval for Lupin's sNDA for Antara capsules

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

FDA approves Mylan's ANDA for Fenofibrate Tablets

FDA approves Mylan's ANDA for Fenofibrate Tablets

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis